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PP-112 Analysis of ﬁve HBeAg-positive patients with
Chinese herb Kuanxiongjiedu grain anti-HBV
infection treatment
Lequan Min*,1, Yanling Liu2, Jianghe Wang2, Huiwen Hong2,
Suyun Ma2. 1University of Science and Technology Beijing;
2Beijing Xiyuan Hospital, Chinese Traditional Medical Research
Institute of China
Background and objectives: The objectives of the research are
to observe the efﬁcacy of the Chinese Herb Kuanxiongjiedu Grain
(CHKG, consists of 12 ingredients) treatment for the patients
whose HBV DNA levels over 106 copies/mL and analysis the
variations of the patients’ hepatocyte.
Methods: Five patients with HBeAg-positive are selected. They
have baseline ALTs: 22.3∼285U/L, HBV DNAs: 2.1×106∼2.8×108
copies/mL. The patients received CHKG two times daily (24g
each time) for 32 weeks. The ALT and HBV DNA tests were
implemented every two weeks in the ﬁrst three months, and
taken every four weeks in the following months. A Ultrasound
Scanner was used to scan the patients and a normal person’s
livers. The mean and standard deviation of the gray levels of the
normal person’s scanned liver image are selected as the standard
of normal liver.
Results: At the week 32, one patient’s HBV DNA was below 1000
copies/mL and had normal ALT; three patient’s HBV DNAs and
ALTs have no signiﬁcant changes; one patient’s HBV DNAs have
signiﬁcant changes. Except the ﬁrst patient, the patients’ normal
liver pixels increased 14% ∼ 51%.
Conclusion: The CHKG may help to recovered the chronic HBV
patients’ damaged hepatocyte even the patients’ virus levels
were not be suppressed during the therapy. Further investigation
should be implemented.
Acknowledgments: This work is jointly supported by the Na-
tional 11-5 Key Special Project of China (No. 2008ZX10502) and
the NNSF of China (No. 60674059).
PP-113 Sequence analysis and replication ﬁtness of the
complete hepatitis B virus genome in patients
with chronic hepatitis B
Dong Ji *, Yan Liu. Viral Hepatitis Research Laboratory, Institute
of Infectious Diseases, 302 Hospital of PLA, Beijing, China
Objective: To analyze the complete HBV genome in patients and
evaluate its replication capacity.
Fig. 1. Schematic diagram of the point mutations analyzed in the study. In
the ﬁrst part of the ﬁgure, the nunber on the top of the full HBV genome
refers to the EcoRI site (3215/0). Position of the four open reading frames
(ORFs) encoding preC/core, preS1/preS2/S, polymerase (Pol), and X protein
are shown by the gray rectangle and the arrow indicates the transcription
direction. The four cis-elements (enhancers and promoters) are indicated
by the open triangle. The numbers under the full HBV genome represent the
nucleotide positions of the studied mutations. In the second part of the
ﬁgure are listed amino acid mutations in both polymerase (RT domain) and
envelope genes-associated domains (S domain).
Methods: The full-length HBV genome ampliﬁcation, cloning,
and sequencing were preformed. Genotype and mutation sites
related to antiviral agents were analyzed, and site-directed mu-
tagenesis was performed on interested sites. The full-length HBV
genomes were transfected into HepG2 and Huh-7 cell lines. 72 h
after transfection, expression of HBsAg was detected with ELISA,
quantitation of intracellular HBV replicative intermediates were
examined by qPCR.
Results: 12 different clones were obtained. several mutation
sites, such as A181V/S, V84M, were identiﬁed, and the better
management of 5 patients was developed.
Fig. 2. Relative replication yield of HBV mutants.
Conclusion: Vector-free replication assay is an approach to
determine the phenotype of clinical HBV strains, which could be-
come an important tool for the management of patient infected
with HBV.
PP-114 Correlation factors involved in therapeutic
efﬁcacy of adefovir dipivoxil for chronic hepatitis
B with YMDD mutation
Yuan-wang Qiu*, Xiang-hu Jiang, Li-hua Huang. Wuxi Infectious
Disease Hospital
Background: To investigate the correlation factors associated
with the therapeutic efﬁcacy of adefovir dipivoxil for chronic
hepatitis B with YMDD mutation.
Methods: 92 patients were enrolled and treated with adefovir
dipivoxil for 48 weeks, Logistic regression analysis was used
to identify some possible correlation factors associated with
therapeutic efﬁcacy.
Results: Patients who achieved undetectable HBV DNA at week
48 of the treatment were found to have a lower baseline HBV
DNA levels compared with those who did not achieve,and the
same result in patients who achieved HBeAg seroconversion
and serum alanine aminotransferase (ALT) normalization. There
were signiﬁcant difference between patients whose baseline ALT
levels ≤1 ULN,HBV DNA levels ≤5.0 lgcopies/mL and patients
whose baseline serum ALT levels >1 ULN,HBV DNA levels >5.0
lgcopies/mL in undetectable HBV DNA (χ2=17.321, P<0.001),
HBeAg seroconversion (χ2=3.88, P=0.049) and ALT normalization
rates (χ2=25.526, P<0.001) after 48-week treatment. Logistic
regression analysis indicated the baseline HBV DNA levels, unde-
tectable serum HBV DNA by PCR at week 24, and undetectable
serum YMDD mutation at week 12 were correlation factors of
therapeutic efﬁcacy at week 48.
Conclusion: Better response at week 48 has signiﬁcantly asso-
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ciated with the lower baseline serum HBV DNA levels, HBV DNA
negativity at week 24 and undetectable serum YMDD mutation
at week 12 compared with non-response. Early treatment with
adefovir dipivoxil for the patients with YMDD mutation who had
virological breakthrough and without biochemical breakthrough
can reach for better curative effect.
PP-115 Hepatitis B vaccination of chronic HBV infected
cases who lost HBsAg during follow-up
Mohammad Reza Hasanjani Roushan*,1,2, Mohammad Jafar
Soleimani Amiri 1,2, Hassan Taheri 1,2, Mohammad Pouralijan3.
1Yahyanejad Hospital; 2Babol Medical University; 3Razi Medical
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Background: Over time, the levels of HBsAg in some chronic HBV
infected individuals declines and is not detectable in the serum.
The purpose of this study was to assess the efﬁcacy of HBV
vaccine in subjects who lost their HBsAg with not seroconverssion
to anti-HBs.
Methods: From April 1993 to December 2007, among 1603 chronic
HBV infected individuals, 34 subjects (22 males, 12 females) be-
came HBsAg negative with no detectable anti-HBs and HBV DNA
in their sera. They received HBV vaccine at 0, 1 and 6 months
(case group). Fifty-two subjects (30 males, 22 females) who were
negative to HBsAg, anti-HBs and anti-HBc received HBV vaccine
like the above schedule (control group). Anti-HBs was assessed
one month of the last dose in these two groups.
Result: The mean age of the case group was 38±12.7 and the
control group was 33.4±8.6 years (p=0.07). The distribution of
sexes between these two groups were equal (p=0.652). The mean
year of follow-up for the case group was 7.6±4.5 years. Anti-HBs
levels ≥10 IU/l was developed in 8 (23.5%) subjects in the case
group and in 45 (86.5%) of the control group (p=0.0001). The
mean anti-HBs levels in the case group was 68±32.66 and in the
control group was 344.6±38.9 IU/l (p=0.00001).
Conclusion: The results show that nearly 24% of chronic HBsAg
positive subjects, who lost their HBsAg responded to hepatitis B
vaccine and the remaining cases need to be followed for occult
HBV infection.
PP-116 Proﬁle of occult hepatitis B virus infection in an
area with intermediate prevalence of HBV
infection
Shanmugam Saravanan*,1, Vijayakumar Velu2, Vidya Madhavan1,
Kailapuri G. Murugavel1, Pachamuthu Balakrishnan1, Sunil
S. Solomon1, Nagalingeswaran Kumarasamy1, Suniti Solomon1,
Sadras P. Thyagarajan3. 1YRG CARE, Chennai, India; 2Emory
Vaccine Research Centre, Atlanta, USA; 3Ramachandra Medical
University, Chennai, India
Background & Aim: Hepatitis B virus (HBV) infection with unde-
tectable levels of hepatitis B surface antigen (HBsAg) is called an
occult infection, which although has been described among sub-
jects with chronic hepatitis C liver disease in the western world,
it’s prevalence and clinical signiﬁcance are still ambiguous in the
Indian subcontinent.
Methods: We investigated HBV-DNA PCR in serum samples of 260
HBsAg negative subjects with chronic HCV-related liver disease,
and 70 apparently healthy volunteers negative for HBsAg and
anti-HCV as control.
Results: Serum samples found positive by at least two indepen-
dent PCR assays were considered HBV DNA positive. HBV-DNA
was detected among 19 HCV-related chronic liver disease (CLD)
patients (7.3%), which was higher (p=0.2) as compared with
the control volunteers (4.3%). It was more frequent (37.5%) in
24 anti- HBs negative/anti-HBc positive patients than in 180
anti-HBs/anti-HBc positive (5%, p<0.05). HCV RNA by qualitative
PCR was signiﬁcantly (p<0.001) higher in occult HBV compare to
non-occult. HCV genotype 1b was predominantly associated with
occult HBV (73%), especially among subjects with hepatocellu-
lar carcinoma (HCC) (p<0.05) as compared to non-occult HBV
cases. Though not signiﬁcant, frequency of occult HBV infection
was higher than healthy controls and HCV 1b genotype was
signiﬁcantly associated in patients with HCC.
Conclusion: This study suggests that in all HBV-endemic areas,
the possibility of occult HBV in patients with HCV should be
considered and HBV-DNA should be performed.
PP-117 Thymosin alpha-1 therapy in Chinese patients
with chronic hepatitis B: results from a
randomized controlled clinical trial
Lin Zhuang*,1, Jing You2, Hong-Ying Chen2, Bao-Zhang Tang2,
Meng-Ling Huang2, Yong-Liang Ma1, Jun-Hua Huang3,
Rong-Xue Wu2. 1Department of Hepatology, Third Municipal
People’s Hospital of Kunming, China; 2Department of Infectious
Diseases, The First Afﬁliated Hospital of Kunming Medical
University, Kunming, China; 3Department of Infectious Diseases,
Yunnan General Hospital of The Chinese People’s Armed Police
Forces, China
Objective: To observe the efﬁciency of Thymosin-α1 treatment
in patients with chronic hepatitis B.
Methods: Fifty-six HBeAg-negative and sixty-two HBeAg-positive
patients were randomly divided two groups, received Thymosin-
α1 or Interferon alpha for six months respectively.
Results: At the end of treatment, complete response (CR) oc-
curred in 8 of 26 and 9 of 29 in T-α1 group and in 14 of 30 and
15 of 33 in IFN-α group in HBeAg-negative and HBeAg-positive
patients respectively (p>0.05). After a 6-month follow-up pe-
riod, a CR was observed in 11 of 26 HBeAg-negative and 14 of
29 HBeAg-positive in T-α1 group and in 7 of 30 HBeAg-negative
and 9 of 33 HBeAg-positive patients in IFN-α group (p>0.05).
Compared with the results observed in untreated patients, the
rate of CR was signiﬁcantly higher in IFN-α group at the end of
therapy (p<0.001) and in T-α1 group at the end of follow-up
(p<0.001). Ten of the 12 T-α1 responders experienced sustained
non-detectable HBVDNA after the 6-month treatment period.
Six of the 14 T-α1 non-responders showed delayed response of
non-detectable HBVDNA during the follow-up period. In HBeAg-
positive patients, it is 87.5% and 53.8%. However, the data were
50% and 0%, 59.1% and 0% in IFN-α group, respectively. The rate of
delayed response was signiﬁcantly higher in T-α1 group (p=0.010)
and the rate of ﬂare was higher in IFN-α group (p>0.05) during
the follow-up period.
Conclusion: A 6-months course of T-α1 therapy is effective in CHB
patients with a gradual and more sustained ALT normalization
and HBVDNA loss.
PP-118 Adefovir genotypic resistance in chronic hepatitis
B patients with virological breakthrough during
adefovir treatment
Song Yang*,1, Jinmei Zheng1, Qi Wang1, Huichun Xing2, Ben Li 2,
Ya Liu2, Wen Xie2, Jie Yan2, Jun Cheng1. 1Institue of Infectious
Diseases, Capital Medical University, Beijing Ditan Hospital,
Beijing, China; 2Center of Liver Diseases, Beijing Ditan Hospital,
Beijing, China
Objectives: To investigate the genotypic resistance proﬁles in
chronic hepatitis B patients who underwent virological break-
through during adefovire treatment.
Methods: Serum samples and clinical data were collected from
adefovir treated patients (10mg/d) who underwent virological
breakthrough (HBV DNA increase 1log10 copies/ml from the
Nadir). Adefovir genotypic resistance was detected with PCR
product pyrosequencing. HBV genotypes were identiﬁed by phy-
logenetic tree analysis of PCR product di-deoxy sequencing
